AbbVie Inc. Files Routine 8-K Report

Ticker: ABBV · Form: 8-K · Filed: 2024-09-10T00:00:00.000Z

Sentiment: neutral

Topics: routine-filing, corporate-governance, financial-reporting

Related Tickers: ABBV

TL;DR

ABBV filed a standard 8-K, no major news.

AI Summary

On September 6, 2024, AbbVie Inc. filed an 8-K report detailing amendments to its articles of incorporation or bylaws and financial statements. The filing does not disclose specific new financial figures or material events beyond routine reporting requirements.

Why It Matters

This filing serves as a standard update for investors, confirming routine corporate actions and financial reporting without indicating any immediate significant changes to the company's operations or financial health.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain information about any significant new risks or material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by AbbVie Inc.?

The primary purpose of this 8-K filing is to report amendments to AbbVie Inc.'s articles of incorporation or bylaws and to file financial statements and exhibits.

What is the accession number for this 8-K filing?

The accession number for this 8-K filing is 0001104659-24-098564.

On what date was this 8-K report filed?

This 8-K report was filed on September 10, 2024.

What is AbbVie Inc.'s fiscal year end?

AbbVie Inc.'s fiscal year end is December 31.

Does this filing indicate any new material events or financial changes?

Based on the provided text, this filing appears to be routine and does not explicitly detail any new material events or significant financial changes beyond standard reporting requirements.

From the Filing

0001104659-24-098564.txt : 20240910 0001104659-24-098564.hdr.sgml : 20240910 20240910153045 ACCESSION NUMBER: 0001104659-24-098564 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240906 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240910 DATE AS OF CHANGE: 20240910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241289920 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2423380d1_8k.htm FORM 8-K false --12-31 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-09-06 2024-09-06 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-09-06 2024-09-06 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-09-06 2024-09-06 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-09-06 2024-09-06 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-09-06 2024-09-06 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-09-06 2024-09-06 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-09-06 2024-09-06 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-09-06 2024-09-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549       FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 6, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.1

View on Read The Filing